LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Strona główna・Stock List・Editas Medicine Inc

Editas Medicine Inc

Closed

SectorHealthcare

2 5.82

Buy Sell

Overview

Share price change

24h

Current

Min

1.96

Max

2.03

Key metrics
By Trading Economics
Income	28M -25M
Sales	4M 7.5M
Profit margin	-332.984
Employees	246
EBITDA	27M -22M

Recommendations
By TipRanks
Recommendations	Sell
12 Months Forecast	+100% upside

Dividends
By Dow Jones
Next Earnings	11 mar 2026

Market Stats
By TradingEconomics
Market Cap	-65M 210M
Previous open	-3.82
Previous close	2

News Sentiment

By Acuity

50%

128 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.33 / 1.54 Support & Resistance

Editas Medicine Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 mar 2026, 19:32 UTC

Acquisitions, Mergers, Takeovers

Diana Shipping Increases Offer to Acquire Genco -- Update

8 mar 2026, 23:47 UTC

Market Talk

Major News Events

Global Equities Roundup: Market Talk

8 mar 2026, 23:47 UTC

Market Talk

Major News Events

Nikkei May Fall on Higher Energy Prices, Signs of U.S. Econ Weakness -- Market Talk

8 mar 2026, 23:46 UTC

Market Talk

Major News Events

Gold Falls Amid Dollar's Strength -- Market Talk

8 mar 2026, 23:34 UTC

Market Talk

Major News Events

Oil Futures Surge Above $100/bbl Amid Growing Middle East Conflict -- Market Talk

8 mar 2026, 23:08 UTC

Major News Events

Front-month WTI Crude Futures Jump 16.6%, Front-Month Brent Crude Futures Climb 15.2%

8 mar 2026, 23:05 UTC

Major News Events

Front-month Crude Oil Futures Surge Amid Rising Middle East Conflict

8 mar 2026, 22:37 UTC

Major News Events

The Long-Feared Persian Gulf Oil Squeeze Is Upon -2-

8 mar 2026, 22:37 UTC

Major News Events

The Long-Feared Persian Gulf Oil Squeeze Is Upon Us -- WSJ

7 mar 2026, 02:30 UTC

Major News Events

Iran War Is Kicking India When It's Already Down -- Barrons.com

6 mar 2026, 22:26 UTC

Major News Events

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mar 2026, 22:07 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mar 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6 mar 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mar 2026, 21:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

6 mar 2026, 21:37 UTC

Earnings

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mar 2026, 21:25 UTC

Major News Events

How The Iran War Impacts Ukraine. -- Barrons.com

6 mar 2026, 21:17 UTC

Earnings

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mar 2026, 20:50 UTC

Earnings

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mar 2026, 20:46 UTC

Earnings

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mar 2026, 20:31 UTC

Major News Events

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mar 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mar 2026, 20:12 UTC

Market Talk

Major News Events

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mar 2026, 19:10 UTC

Market Talk

Major News Events

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mar 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mar 2026, 18:44 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mar 2026, 18:08 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 18:04 UTC

Earnings

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 18:04 UTC

Earnings

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

Peer Comparison

Price change

Editas Medicine Inc Forecast

Price Target

By TipRanks

100% upside

12 Months Forecast

Average 4 USD 100%

High 4 USD

Low 4 USD

Based on 2 Wall Street analysts offering 12 month price targets forEditas Medicine Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Editas Medicine Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.33 / 1.54Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

128 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.